Phase 1, First-In-Human, Dose-Finding And Expansion Study To Evaluate Xmab®808 In Combination With Pembrolizumab In Advanced Solid Tumors
Posted Date: Apr 26, 2024
- Investigator: Trisha Wise-Draper
- Specialties: Colorectal Cancer, Head and Neck Cancer, Lung Cancer
- Type of Study: Drug
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of intravenous (IV) administration of XmAb808 in combination with pembrolizumab in subjects with selected advanced solid tumors and to identify the minimum safe and biologically effective/recommended dose (RD) and schedule for XmAb808.
Criteria:
Null
Keywords:
Castration Resistant Prostate Cancer, Colorectal Cancer, Head And Neck Squamous Cell Carcinoma
For More Information:
Kayla Webb
NULL
cancer@uchealth.com